Table 1.
Patient disposition from study treatment: maintenance period (UNCOVER‐1 and UNCOVER‐2)
| IXEQ2W/PBO N = 211 | IXEQ2W/IXEQ4W N = 221 | IXEQ4W/PBO N = 191 | IXEQ4W/IXEQ4W N = 195 | |
|---|---|---|---|---|
| Completed Period, n (%) | 23 (10.9) | 184 (83.3) | 18 (9.4) | 143 (73.3) |
| Relapsed, n (%) | 176 (83.4) | 27 (12.2) | 157 (82.2) | 36 (18.5) |
| Discontinued, n (%) | 11 (5.2) | 11 (5.0) | 16 (8.4) | 17 (8.7) |
| Adverse event | 2 (0.9) | 6 (2.7) | 6 (3.1) | 7 (3.6) |
| Subject decision | 3 (1.4) | 2 (0.9) | 6 (3.1) | 4 (2.1) |
| Lost to follow‐up | 3 (1.4) | 1 (0.5) | 3 (1.6) | 3 (1.5) |
| Death | 0 | 1 (0.5) | 0 | 1 (0.5) |
| Investigator decision | 0 | 1 (0.5) | 0 | 1 (0.5) |
| Lack of efficacy | 1 (0.5) | 0 | 0 | 1 (0.5) |
| Protocol violation | 1 (0.5) | 0 | 1 (0.5) | 0 |
IXEQ2W, ixekizumab 80 mg every 2 weeks; IXEQ4W, ixekizumab 80 mg every 4 weeks; N, population size; n, number in group; PBO, placebo.